

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No issues identified during scoping

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No issues raised

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No issues identified

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

N/a (minded no)

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

N/A

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

N/a

Approved by Associate Director (name): Elisabeth George on behalf of Helen Chung

Date: 14/10/2010

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No issues identified.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

Yes. When using the disease activity score (DAS28), healthcare professionals should take into account any physical, sensory or learning disabilities, communication difficulties, or disease characteristics that could

adversely affect patient assessment and make any adjustments they consider appropriate.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Committee has alleviated barriers by including an additional recommendation (1.3) in its guidance that uses the text in 2 above.

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 06/07/2011